The industry's own research.
179 items
showing 61–120 of 179
Planning permission has been approved by Camden Council for the KOVA KX development to be tailored to meet the operational requirements of its future occupier, LifeArc.
A 70,000 sq ft life sciences property (Kova KX) has been pre-let to LifeArc in a major UK letting transaction.
DivcoWest said Monday that Collegium Pharmaceutical has signed a headquarters lease for 40,288 square feet on floors 11 and 12 at One Lincoln in Boston’s Financial District, relocating from suburban Stoughton, MA. Slated for the first quarter of 2027, Collegium’s arrival adds a life science presence to a tenant…
Alexandria Real Estate Equities, Inc. has delivered a 427,000-square-foot research & development hub for Bristol Myers Squibb (BMS) at the Campus Point by Alexandria Megacampus in San Diego. Since 1998, Alexandria has partnered with BMS across the REIT’s life science and advanced technology clusters. The initial…
An analysis of Spain's strategic positioning and development within the European life sciences real estate market.
The 14th Five-Year Plan supports Hong Kong to develop into an international innovation and technology (I&T) centre. This paper examines some potential opportunities in Northern Metropolis to respond to and capitalise on the national development strategies.
Capital Economics examines life science real estate fundamentals and performance outlook, noting pandemic-driven reinforcement of long-term demand despite recent supply constraints.
Exploration of how the 5th Industrial Revolution and AI adoption are reshaping real estate strategies and asset positioning.
This is a viewpoint-commentary published by Institutional Real Estate, Inc. in April 2026 addressing how demand in Asia Pacific life sciences and research and development real estate can be converted into investment opportunities. The piece covers topics related to capital markets and economic considerations in this property sector.
Analysis of office-to-alternate-use conversion trends, arguing that life sciences properties experienced greater market impact than multifamily adaptive reuse projects.
Market data on life sciences leasing activity in the first half of 2025, showing below-pre-pandemic levels with regional variations in recovery.
This is a market report published by CBRE in April 2025 covering the life sciences sector in Sydney, Australia. The report is part of CBRE's Global Life Sciences Atlas series and provides market intelligence for the Asia-Pacific region focused on the Sydney market.
This is a market report published by CBRE in April 2025 covering the life sciences sector in the San Francisco Bay Area. The report provides analysis of the regional life sciences real estate market with national context.
This is a market atlas published by CBRE in April 2025 covering the life sciences sector in the Los Angeles market. The resource provides geographical and sectoral analysis relevant to the commercial real estate intelligence library's coverage of life sciences real estate.
This is a market report published by CBRE in April 2025 covering the life sciences sector in the Boston-Cambridge area. The report appears to be part of a broader global atlas examining life sciences real estate markets.
This is a market atlas published by CBRE in April 2025 covering the life sciences sector in the Seattle market, with national geographic scope. The document provides an overview of the global life sciences real estate landscape as it relates to the Seattle region.
This is a market report published by CBRE in April 2025 covering the life sciences sector in the Washington, DC-Baltimore market area.
This is a market atlas published by CBRE in April 2025 covering the life sciences sector in Singapore within the Asia-Pacific region.
This is a market report published by CBRE in April 2025 covering the life sciences sector in Melbourne, Australia. The report is part of CBRE's Global Life Sciences Atlas series and focuses on the Asia-Pacific region.
This is a market report published by CBRE in April 2025 covering the life sciences sector in the New York City market. The report is part of CBRE's Global Life Sciences Atlas series and includes geographic focus on New York State and national scope.
This is a market report published by Newmark in the fourth quarter of 2025 providing an overview of the life sciences sector in Boston, Massachusetts.
This is a market report published by Newmark in the first quarter of 2025 covering the life science sector in the San Francisco Bay Area.
adMare BioInnovations opened a 30,000 SF ready-to-use wet-lab facility in Vancouver via a long-term lease, already hosting startups.
BlueRock Therapeutics signed a long-term lease for ~80,000 SF at Seeker Labs' Catalyst facility, Toronto's first privately funded purpose-built life-sciences building in 20+ years.
Duracell leased two full floors (59,000 SF) at the Trammell Crow-developed Science Square Labs tower near Georgia Tech for an R&D headquarters.
Telix officially opened Telix Manufacturing Solutions North Melbourne, a purpose-built radiopharmaceutical research, manufacturing and treatment facility.
Children's Medical Research Institute filed a $272.4m two-phase Gene Technologies Building at Westmead.
CG Oncology, Highlander Health Partners and LH Capital are expanding into the 16th floor of Pegasus Park's tower.
UChicago signed for over 155,000 SF at the 13-story, 300,000+ SF Hyde Park Labs for cancer, biochemistry and molecular-biology research.
CapitaLand Development and CapitaLand Ascendas REIT jointly opened Geneo at Singapore Science Park, a S$1.4bn life-sciences/business-park hub.
Seattle Children's Research Institute moved into 124,000 sq ft at 1916 Boren, an 11-story life-sciences building developed by Trammell Crow.
Hansoh Bio leased the entire 2nd/3rd floors (32,000 SF) at Research Square, Rockville, in the DC-Baltimore life-sciences cluster.
TransMedics signed a 16-year, full-building lease (498,000 SF) at BioMed Realty's Assembly Innovation Park in Somerville for its new global HQ and manufacturing hub.
Jackson Laboratory leased 41,000 SF at 619 West 54th Street's Hudson Research Center, owned by Taconic Partners' Elevate Research Properties.
British Land agreed a recommended cash-and-share offer for Life Science REIT PLC valued at approximately GBP 150 million (42.8p/share: 14.1p cash plus 0.07 new British Land shares), a 21% premium to LABS' prior close, implemented via a Part 26 scheme of arrangement. The deal gives British Land five 'Golden Triangle' life-science assets across London, Oxford and Cambridge; it completed 20 April 2026 with Life Science REIT re-registered as a private company.
Analysis of evolving demand dynamics in Germany's life sciences real estate sector, highlighting increased selectivity and the growing importance of standardized processes, regulatory frameworks, and suitable space availability.
Roche is decommissioning the specialized clinical testing laboratory it inherited from its 2015 Ariosa Diagnostics acquisition and moving all 45 employees roughly nine miles north to a purpose-built 11,300-square-foot lab on its Santa Clara campus, a consolidation triggered by a lease expiration and executed…
While pharmaceutical companies acquire sponsor-backed biotech companies, corporate real estate teams are becoming more responsible for preserving the value of those deals, according to a new CBRE insight. Even as acquired biotech firms tend to have smaller real estate footprints and leaner workforces, they become…
In the labor market, life sciences hubs continue to rely on talent to drive innovation. According to Cushman & Wakefield’s 2026 Life Sciences Labor Dynamics Across Key U.S. Markets report, labor is also essential for site selection. Report authors Sandy Romero (Head of Office & Alternatives) and Maggie Tillotson…
Colliers analysis of Peninsula R&D market conditions showing early stabilization signals and life sciences activity recovery.
Colliers analysis of capitalization rate trends across Asia-Pacific markets, noting compressed cap rates in sectors with low vacancy and strong space demand, alongside gradually declining interest rates.
Cushman & Wakefield's forward-looking analysis of real estate market trends, drivers, and forecasts across the Asia-Pacific region.
Upside Foods, the cultivated meat company that raised more than $600 million at a billion-dollar valuation and then cut staff three times in 13 months, has leased 18,505 square feet at 6101 Christie Avenue in Emeryville, a lease that appeared on the Bay Area’s life sciences roster in the same quarter that a nearby…
Natera, the multibillion-dollar genetic testing company that moved its headquarters to Austin but kept its scientific core on the Peninsula, has leased 19,652 square feet at 2 Tower Place in South San Francisco, a Ventas-owned tower where the commitment lands as the company’s existing South San Francisco lease…
The Greater Boston lab market posted its first quarter of positive net absorption in nearly a year for the second quarter of 2026, representing what CBRE called “a tentative sign of stabilization amid persistent headwinds.” Total market availability edged up 10 basis points from Q1 and 60 bps from Q2 2025 to 32.8%,…
Clinical-stage breast cancer company Olema Oncology has committed to 38,176 square feet at Kilroy Realty’s 365 Oyster Point Boulevard under a seven-year lease, relocating its headquarters out of San Francisco and pushing the building to roughly 60 percent leased months before the pivotal readout that will determine…
The life sciences real estate sector in Greater Boston still has a deep hole to dig out of, with millions of square feet of lab buildings sitting vacant, but a new report shines a positive light on the future of the market’s demand.
Moody's CRE Analytics publishes performance metrics for the technology sector real estate market in Q4 2024.
CBRE publishes quarterly figures on the Bay Area life sciences real estate market.
Market intelligence covering UK life science real estate trends, occupier demand, investment activity, and asset valuations.
CBRE examines hidden real estate considerations and cost factors that arise during mergers and acquisitions in the life sciences sector.
Capital Economics examines how alternative real estate sectors are positioned to benefit from structural trends and lower cyclical sensitivity in a weak economic growth environment.
Capital Economics shares insights and outlook perspectives on alternative real estate assets drawn from client roundtable discussions.
Research evaluating risks and opportunities in converting office buildings to life science, medical, and multifamily uses, based on market data and interviews with developers and architects.
Research examining how REITs invested in tech-related property sectors can reduce portfolio volatility and provide exposure to 21st century real estate.
An examination of key success factors in life sciences real estate development and the outlook for capital deployment in the biotech sector.
Carter Jonas' biannual update on life sciences sector outlook across UK key markets including Oxford, Cambridge, and London.
CBRE examines the intersection of high-performance computing, life sciences research, and artificial intelligence as drivers of real estate demand and innovation infrastructure.
This is a sector spotlight report published by CBRE on June 24, 2026, examining six talent trends within the life sciences industry and their connection to property demand across national markets.
1. The market is correcting, not collapsing Speaker credit: Jeff Myers, Nader Elrashidy The life sciences market has clearly moved out of its peak-growth phase, but that does not mean the sector is broken. The better read is that the market is recalibrating after several years of rapid expansion, heavy investment,…